Aberrantly expressed Bruton ’s tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells
ConclusionsFrom our data we conclude that BTK is a therapeutically targetable driver of neuroblastoma.Graphical abstract
Source: Cellular Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Cancer & Oncology | Genetics | Neuroblastoma | Neurology | Stem Cell Therapy | Stem Cells